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Health screening tests have a great impact on the public's health because they involve testing 
asymptomatic populations for specific diseases or health conditions for secondary 
prevention when interventions may halt or diminish disease progression before appearance 
of clinical signs and symptoms. The U.S. Preventive Services Task Force (USPSTF),1 
supported by the Agency for Healthcare Research and Quality, is widely considered to be 
the leading independent panel of experts in recommendations about disease prevention and 
in primary and secondary interventions. This organization conducts rigorous and impartial 
assessments of the scientific evidence for effectiveness of a broad range of clinical 
preventive services, including health screening.
According to the World Health Organization, all of the following criteria must be met in an 
effective screening program: significant societal burden; detectable asymptomatic phase; 
screening test accuracy; acceptability, availability, and feasibility; effective prognostication 
and intervention for those who screen positive; cost-effectiveness; and assurance of 
informed consent and patient confidentiality.2 In providing recommendations, the USPSTF 
considers these criteria but does not strictly use them when evaluating screening tests.
For example, if a screening test has been evaluated in a randomized control trial and has 
been shown to result in better outcomes for those in the screening group, the USPSTF does 
not consider cost-effectiveness. All screening recommendations are rated by the USPSTF 
into one of five grades:3
• ‘A’ for strong recommendation with high certainty that net benefit is substantial,
• ‘B’ for recommendation with high certainty that net benefit is moderate or 
moderate certainty that net benefit is moderate to substantial,
• ‘C’ for individualized decision making with at least moderate evidence that net 
benefit is small,
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• ‘D’ against screening with moderate to high certainty that net benefit is close to 
zero or harms outweigh benefits, and
• ‘I’ is a statement that no recommendation can be made due to available evidence 
that is insufficient, of poor quality, or conflicting, making it not feasible to 
objectively evaluate the net balance between health benefits and harms of 
screening.
Health screening should be offered or provided for A and B recommendations. C 
recommendation implies that screening should be offered or provided for selected patients 
depending on individual circumstances.3 For D recommendation, screening should be 
discouraged. For I recommendation, if screening is offered, patients should understand the 
uncertainty about the balance of health benefits and harms.4
In this article, the recommendations of the USPSTF for all laboratory-based screening tests 
for or relevant to adult women are presented, along with a brief rationale based on 
evaluation of the balance of health benefits and harms. Some of these recommendations 
apply to both men and women, and they are also included. When applicable, specific CDC 
recommendations are also described. A previous article had described selected laboratory-
based screening tests for aging males.5 Laboratory screening tests described are those used 
for the risk of coronary heart disease; endocrine and metabolic disorders (chronic kidney 
disease, diabetes mellitus, hereditary hemochromatosis, and thyroid disease); infectious 
diseases caused by chlamydia, genital herpes, gonorrhea, hepatitis B virus (HBV), hepatitis 
C virus (HCV), human immunodeficiency virus (HIV), and syphilis; cancer of the bladder, 
cervix, colon and rectum, lung, ovaries, and pancreas; and substance abuse. This article is 
meant to provide the reader with an understanding and appreciation of whether and why 
specific laboratory screening tests should or should not be used for the evaluated diseases or 
conditions, sometimes using different target populations. The tables (see digital version) list 
the USPSTF recommendations for screening of the diseases or conditions relating to adult 
women, along with the recommendation grade for each. Recommendations for laboratory 
screening tests for risk of coronary heart disease; endocrine and metabolic disorders, and 
during pregnancy; infectious diseases; neoplastic diseases; and substance abuse are 
presented and discussed.
Risk of Coronary Heart Disease
For women aged 20 and older at increased risk for coronary heart disease, there is good 
evidence that lipid-lowering drug therapy substantially decreases incidence of coronary 
heart disease in those with abnormal lipids, and there is good evidence that harms from 
screening and treatment are small and include possible labeling and adverse effects 
associated with lipid-lowering therapy such as rhabdomyolysis (A recommendation for 
women 45 years of age or older and B recommendation for those between 20 and 44 years 
of age).6 Good-quality evidence shows that total cholesterol, low-density lipoprotein (LDL)-
cholesterol and high-density lipoprotein (HDL)-cholesterol are independent predictors of 
risk for coronary heart disease, and that total cholesterol/HDL-cholesterol ratio or LDL-
cholesterol/HDL-cholesterol ratio classify risk better than total cholesterol alone.6 Although 
triglycerides level is a strong univariate predictor of cardiovascular events, its association 
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with these events is reduced substantially by adjustment for other risk factors. For women 
aged 20 and older who are not at increased risk for coronary heart disease, individualized 
decision making is recommended, given that there is at least moderate evidence that net 
benefit of screening is small (C recommendation). High-sensitivity C-reactive protein (CRP) 
has been the most rigorously studied nontraditional marker for risk of coronary heart 
disease. However, on the basis of the latest USPSTF review, there is inconclusive evidence 
that considering changes in CRP level lead to primary prevention of coronary heart disease 
events (I recommendation).7 Analyses from four large cohorts were consistent in finding 
evidence that including CRP improves risk stratification among initially intermediate-risk 
persons, that CRP has desirable test characteristics, and that good data exist about the 
prevalence of elevated CRP levels in intermediate-risk persons.8 However, limited evidence 
links changes in CRP levels to primary prevention of cardiovascular events. Other 
laboratory risk markers evaluated by the USPSTF were lipoprotein(a), homocysteine, 
leukocyte count and fasting blood glucose. Current evidence, however, does not support 
routine use of any of these markers for further risk stratification of intermediate-risk 
persons, and there is little evidence to determine harms of using nontraditional markers to 
screen for risk of coronary heart disease. Potential harms of screening include lifelong use of 
medications without proven benefit and psychological harms from being misclassified in a 
higher risk category.
Endocrine/Metabolic Disorders and Pregnancy
Endocrine and Metabolic Disorders
Chronic kidney disease—No clinical trials have evaluated the screening or monitoring 
of chronic kidney disease; therefore, evidence that routine screening improves clinical 
outcomes for asymptomatic adults is inadequate (I recommendation).9,10 Although potential 
harms of screening may include adverse effects from venipuncture and psychological effects 
of labeling a person with the disease, evidence on the harms of screening is inadequate.9 
Patients falsely identified as having the disease, by being tested for urinary protein and 
serum creatinine, may receive unnecessary treatment and diagnostic interventions resulting 
in harmful effects given that there is convincing evidence that medications used to treat 
early disease may have adverse effects.9
Diabetes mellitus—Direct evidence is lacking on the health benefits of detecting type 2 
diabetes by either targeted or mass screening, and indirect evidence also fails to demonstrate 
health benefits for screening the general population.11 However, individuals with 
hypertension probably benefit from screening because blood pressure targets for those with 
diabetes are lower than those without diabetes; and in those with hypertension and diabetes, 
lowering blood pressure below conventional target values reduces the incidence of 
cardiovascular events and mortality.12 Intensive glycemic control in persons with clinically 
detected diabetes mellitus reduces progression of microvascular disease. Screening for type 
2 diabetes every three years in asymptomatic adults with sustained blood pressure (either 
treated or untreated) of greater than 135/80 mm mercury is recommended (B 
recommendation).13 In addition to criteria for plasma or blood glucose measurement, 
diabetes may also be diagnosed by demonstrating increased blood hemoglobin A1c 
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concentrations.14 Observational studies report no serious long-term adverse psychological 
effects such as anxiety from receiving a new diagnosis of type 2 diabetes mellitus from 
screening.12 However, longer-term effects of labeling a large proportion of the population as 
abnormal are unknown. For adults with blood pressure of 135/80 mm mercury or lower, 
there is inadequate evidence that early diabetes control as a result of screening provides an 
incremental benefit for microvascular clinical outcomes compared with initiation of 
treatment after clinical diagnosis given that the benefits of tight glycemic control on 
microvascular clinical outcomes, such as severe visual impairment or end-stage renal 
disease, take years to become apparent (I recommendation).12
Hereditary hemochromatosis—Although available data suggest that 38%-50% of 
C282Y homozygotes develop iron overload and 10%-25% develop some type of 
hemochromatosis-associated morbidity, current research provides very limited numbers of 
observations and research designs are subject to bias.15 There is fair evidence that clinically 
important disease due to hereditary hemochromatosis is rare in the general population, and 
that a low proportion of individuals with a high-risk genotype (C282Y homozygotes) 
manifest the disease.16 Even among these individuals, it appears that only a small subset will 
develop symptoms of hemochromatosis, and an even smaller proportion of them will 
develop advanced stages of clinical disease. Also, the risk of iron overload is reduced further 
for pre-menopausal women due to the monthly menstrual blood loss. There is poor evidence 
that early therapeutic phlebotomy, the primary treatment for hemochromatosis, improves 
morbidity and mortality in screening-detected versus clinically detected individuals.16 
Screening could lead to identification of a large number of individuals who possess high-risk 
genotype but may never manifest clinical disease, and this may result in unnecessary 
surveillance, treatments and invasive work-up, labeling and anxiety. Potential harms of 
genetic screening for hereditary hemochromatosis appear to outweigh its potential benefits 
(D recommendation).16
Thyroid disease—Screening for occult thyroid dysfunction in adults using tests for 
thyroxine (T4) and thyroid-stimulating hormone (TSH) would be valuable if there were 
clinical benefits of early treatment, including relief of previously unrecognized symptoms.17 
Although there is fair evidence that TSH testing can detect subclinical thyroid disease in 
people without symptoms of thyroid dysfunction, there is poor evidence that treatment 
improves clinically important outcomes in adults with screen-detected thyroid disease (I 
recommendation).18 Although yield of screening is greater in certain high-risk groups, such 
as postpartum women as well as those with Down syndrome and the elderly, there is poor 
evidence that screening these groups leads to clinically important benefits; and evidence 
regarding the efficacy of treatment in women found by screening to have subclinical thyroid 
dysfunction is inconclusive.19 Data on adverse effects of the broader use of levothyroxine 
are sparse,19 and there is potential for harm caused by false positive screening tests even 
though the magnitude of harm is unknown.18 As an initial screen for thyroid disease, 
sensitive TSH testing offers the greatest promise.17
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Screening During Pregnancy
Bacterial vaginosis—For pregnant women at low risk for preterm delivery, there is 
moderate certainty that screening for bacterial vaginosis has no net benefit (D 
recommendation).20 For pregnant women at high risk for preterm delivery, evidence is 
conflicting and the balance of benefits and harms cannot be determined (I recommendation).
Bacteriuria—In pregnant women, convincing evidence indicates that detection of and 
treatment for asymptomatic bacteriuria with antibiotics significantly reduces the incidence 
of symptomatic maternal urinary tract infections and low birth weight (A 
recommendation).21 Potential harms associated with treatment for asymptomatic bacteriuria 
include adverse effects from antibiotics and development of bacterial resistance.
Chlamydial infection—There are no studies evaluating effectiveness of screening for 
chlamydial infection in pregnant women who are at increased risk of infection. However, 
screening identifies infection in asymptomatic pregnant women, there is a high prevalence 
of infection among pregnant women at increased risk of infection, and fair evidence of 
improved pregnancy and birth outcomes for women treated for chlamydial infection (B 
recommendation).22 Potential harms of screening include anxiety and various problems 
arising from positive results and over-treatment. Screening with nucleic acid amplification 
testing of urine or vaginal swabs is recommended at the first prenatal visit, and for patients 
with continuing or new risk of infection, screening is also recommended during the third 
trimester.22
Genital herpes simplex virus (HSV) infection—Screening asymptomatic pregnant 
women using serological screening tests for HSV antibody does not reduce transmission of 
genital HSV to newborn infants, and there is no evidence that treating seronegative women 
decreases risk for neonatal infection.23 There is limited evidence that performance of 
Caesarean section in women with active HSV lesions at the time of delivery decreases 
neonatal HSV infection. There is limited evidence of safety of antiviral therapy in pregnant 
women and neonates.23 Potential harms of screening include false-positive test results, 
labeling, and anxiety, as well as false negative tests resulting in false reassurance. The 
potential harms of screening for genital HSV infection outweigh potential benefits (Shahram 
Shahangian recommendation).23
Gestational diabetes mellitus—There is adequate evidence that treatment of screen-
detected gestational diabetes mellitus (B recommendation) with dietary modifications, 
glucose monitoring and insulin if needed can significantly reduce the risk of preeclampsia, 
fetal macrosomia and shoulder dystocia.24 When these outcomes are considered collectively, 
there is a moderate net benefit for both mother and infant.
Gonorrhea infection—Pregnant women with gonorrhea infection are at higher risk for 
premature rupture of membranes, preterm labor, chorioamnionitis, and perinatal 
transmission to infants can cause severe conjunctivitis resulting in blindness if untreated.25 
There is fair evidence that screening tests (culture and nucleic acid amplification tests of 
endocervical swabs, or nucleic acid amplification tests of urine or vaginal swabs) can 
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accurately detect gonorrhea infection, good evidence that antibiotics can cure the infection, 
and fair evidence that screening pregnant women at high risk for gonorrhea may prevent the 
complications associated with gonococcal infection during pregnancy (B 
recommendation).25 Although no study has directly examined harms of screening or 
treatment for gonorrhea infection, potential harms may include opportunity costs to the 
clinician and patient (time and other resources); stress, labeling and further testing due to 
positive or false-positive test results; and harms resulting from adverse drug reactions. At-
risk pregnant women should be screened at first prenatal visit, and for those at continued 
risk or with a new risk factor, a second screening should be conducted during the third 
trimester.25 In women, gonorrhea is a major cause of cervicitis and pelvic inflammatory 
disease, which can lead to ectopic pregnancy, infertility and chronic pelvic pain. However, 
prevalence of gonorrhea infection in pregnant women not at increased risk of infection is 
low, and the balance between benefits and harms of screening in pregnant women not at 
increased risk of infection cannot be determined (I recommendation).
Hepatitis B virus (HBV) infection—Screening for HBV infection in pregnant women to 
identify newborns who will require prophylaxis against perinatal infection is a well-
established, evidence-based standard of current medical practice (A recommendation).26 A 
2006 systematic review of randomized, controlled trials found that newborn prophylaxis 
reduced perinatal transmission of HBV infection. There is good evidence that universal 
prenatal screening for HBV infection using hepatitis B suliace antigen (HBsAg) test 
substantially reduces prenatal transmission of HBV and subsequent development of chronic 
HBV infection.27 Current practice of providing post-exposure prophylaxis with hepatitis B 
immune globulin administered at birth to infants of mothers infected with HBV substantially 
reduced risk for acquiring HBV infection.26 HBsAg test should be ordered at first prenatal 
visit, and pregnant women with unknown HBsAg test status or with new or continuing risk 
factors at admission to hospital, birth center or other delivery setting should be 
(re-)screened.26 Although potential harms of screening are no greater than small, there are 
no published studies that describe harms of screening for HBV infection in pregnant 
women.26
Human immunodeficiency virus (HIV) infection—There is convincing evidence that 
identification and treatment of HIV-positive pregnant women dramatically reduces rates of 
mother-to-child transmission.28 However, no study has directly evaluated the effects on 
clinical outcomes of screening versus no screening for HIV infection.29 Antiretroviral 
therapy in combination with avoidance of breastfeeding and elective Caesarean section in 
women with viremia reduces risk for mother-to-child transmission.30 There is convincing 
evidence that individual antiretroviral drugs, drug classes, and combinations are all 
associated with increased risk for cardiovascular and some short-term adverse events such as 
increased risk of preterm delivery during pregnancy, but the magnitude of such risks appears 
to be small.28 Evidence is insufficient to determine optimum time intervals for HIV 
screening; however, a reasonable approach is one-time screening of all pregnant women to 
identify women who are already HIV-positive, with repeated screening of those known to be 
at increased risk of HIV infection (A recommendation).28
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Iron deficiency anemia—There is fair evidence that treating asymptomatic pregnant 
women who have iron deficiency anemia results in moderate benefits in health outcomes (B 
recommendation).31 However, there is no evidence addressing harms of screening pregnant 
women for iron deficiency anemia. Potential harms include false-positive results, anxiety, 
cost, gastrointestinal symptoms, and unintentional overdose.31
Lead poisoning—Given the significant potential harms of treatment and residential lead 
hazard abatement and no evidence of treatment benefit, the USPSTF concluded that harms 
of screening for elevated blood lead levels in asymptomatic pregnant women outweigh 
potential benefits (D recommendation).32
Rh (D) incompatibility—The USPSTF found good evidence that D blood typing, anti-D 
antibody testing and intervention with Rh(D) immunoglobulin, as appropriate, prevents 
maternal sensitization and improves outcomes for newborns, and these benefits substantially 
outweigh any potential harm.33 Therefore, it is strongly recommended that all pregnant 
women undergo D blood typing and antibody testing during their first prenatal visit (A 
recommendation). There is fair evidence that repeated antibody testing for unsensitized D-
negative women (unless the father is also known to be D-negative) and intervention with D 
immunoglobulin, as appropriate, provides additional benefit over a single test at the first 
prenatal visit in preventing maternal sensitization and improving outcomes for newborns.33 
The benefits of repeated testing substantially outweigh any potential harm; therefore, the 
USPSTF recommends repeated D antibody testing for all unsensitized D-negative women at 
24-28 weeks’ gestation, unless the biological father is known to be D-negative (B 
recommendation).
Syphilis infection—Untreated syphilis during pregnancy is associated with stillbirth, 
neonatal death, bone deformities, and neurologic impairment; and there is adequate evidence 
that screening tests can accurately detect syphilis infection, and convincing observational 
evidence that universal screening of pregnant women decreases proportion of infants with 
clinical manifestations of syphilis infection.34 Nontreponemal tests commonly used for 
initial screening are Venereal Disease Research Laboratory (VDRL) or Rapid Plasma 
Reagin (RPR), followed by confirmatory fluorescent treponemal antibody absorbed (FTA-
ABS) or T. pallidum particle agglutination (TP-PA) tests.35 All pregnant women should be 
tested at their first prenatal visit. Current recommendations for women in high risk groups 
call for screening at first prenatal visit, and again during third trimester (at 28 weeks of 
gestation) and at delivery.36 Although there is no new direct evidence that screening for 
syphilis infection leads to improved health outcomes in persons at increased risk for 
infection, there is adequate evidence that screening tests can accurately detect syphilis 
infection and that antibiotics can cure syphilis.35 Screening and treatment may result in 
potential harms, including false-positive results that require clinical evaluation, unnecessary 
anxiety to the patient and harms of antibiotic use.34,35 Drug-related harms include 
anaphylaxis from penicillin allergy, and Jarisch-Herxheimer reaction occurring within first 
24 hours after treatment.36 Screening of pregnant women is strongly recommended with 
high certainty that net benefit is substantial (A recommendation).
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Screening for Infectious Diseases
Bacteriuria—In nonpregnant women, adequate evidence suggests that screening for 
asymptomatic bacteriuria is ineffective in improving clinical outcomes, and that there is 
moderate certainty that the harms of screening outweigh any potential benefits (D 
recommendation).21
Chlamydia—There is good evidence that screening for chlamydial infection in sexually 
active women ages 24 and younger or older at increased risk of infection can reduce 
incidence of pelvic inflammatory disease, and that benefits of screening these women are 
substantial (A recommendation).22 Potential harms include anxiety and relationship 
problems arising from positive results and over-treatment. The CDC recommends that these 
women be screened at least annually using nucleic acid amplification tests on urine or 
vaginal swabs.37 The 2014 CDC recommendation advises use of nucleic acid amplification 
tests as they are better than other available tests because of their increased clinical sensitivity 
and specificity, and greater ease of specimen transport.38
No studies were identified documenting benefits of screening women older than 24 years of 
age who are not at increased risk for chlamydial infection.22 While recognizing potential 
benefit to women identified through screening, overall benefit of screening would be small, 
given low prevalence of infection among women who are not at increased risk (C 
recommendation).
Genital HSV—There is no evidence that screening asymptomatic individuals with 
serological tests for HSV antibody improves health outcomes or that it reduces transmission 
of this virus.23 There is good evidence that serological screening tests can accurately 
identify those exposed to HSV and that antiviral therapy improves health outcomes in 
symptomatic women, such as those with multiple recurrences. However, there is no 
evidence that use of antiviral therapy improves health outcomes in those with asymptomatic 
infection.23 Potential harms of screening include false-positive test results, labeling, and 
anxiety, as well as false negative tests resulting in false reassurance. Harms of screening for 
genital HSV infection outweigh potential benefits (D recommendation).23
Gonorrhea—Women with asymptomatic gonorrhea infection have high morbidity due to 
pelvic inflammatory disease, ectopic pregnancy, and chronic pelvic pain.25 There is fair 
evidence that screening tests (culture and nucleic acid amplification tests of endocervical 
swabs, or nucleic acid amplification tests of urine or vaginal swabs) can accurately detect 
gonorrhea infection, good evidence that antibiotics can cure the infection, and fair evidence 
that screening women at high risk for gonorrhea may prevent complications associated with 
gonococcal infection (B recommendation). Although no study has directly examined harms 
of screening or treatment for gonorrhea infection, potential harms may include opportunity 
costs to the clinician and patient (time and other resources); stress, labeling, and further 
testing; and side effects of medications.25 Optimal screening interval for non-pregnant 
women at increased risk for gonorrhea infection is not known.
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There is a low prevalence of gonorrhea infection in the general population and consequently 
a low yield from screening; therefore, harms such as false-positive test results, labeling in 
low-prevalence populations, and adverse effects of drugs used in treatment outweigh any 
potential benefits (D recommendation).25
Hepatitis B Virus (HBV)—There is no evidence that screening the general population for 
HBV infection improves long-term health outcomes such as cirrhosis, hepatocellular 
carcinoma, or mortality.27 Prevalence of HBV infection is low, and the majority of infected 
individuals do not develop chronic infection, cirrhosis, or HBV-related liver disease. No 
studies were identified that addressed whether routine screening of asymptomatic 
individuals in clinical settings was an effective method of reducing HBV infection in the 
general population, and that early screening and detection of HBV infection reduced 
morbidity and mortality associated with chronic carrier state of HBV infection.39 No studies 
were identified that addressed effectiveness of routine screening of high-risk individuals for 
purposes of referral for HBV vaccination. Potential harms of screening include labeling, and 
they are likely to exceed any potential benefits (D recommendation).27
Hepatitis C virus (HCV)—There is no direct evidence on benefit of screening for HCV 
infection in asymptomatic adults in reducing morbidity and mortality; however, there is 
adequate evidence that antiviral regimens result in sustained virologic and improved clinical 
outcomes.40 Given accuracy of the screening test (anti-HCV antibody testing followed by 
confirmatory nucleic acid amplification testing41) and availability of effective interventions 
for HCV infection, screening is of moderate benefit for populations at high risk and those 
born in 1945-1965 (B recommendation).40 There is limited evidence on harms of screening 
for HCV; potential harms of screening include anxiety, patient labeling, and feelings of 
stigmatization. There is adequate evidence on harms associated with diagnostic evaluation 
used to guide treatment decisions such as liver biopsy; and these harms include bleeding, 
infection, and severe pain in approximately 1% of persons having liver biopsy and death in 
up to 0.1% of them.40 While there is adequate evidence that antiviral therapy regimens may 
be associated with fatigue, headache, flu-like symptoms, hematologic events and rash, 
therapy is given only for a defined duration, and serious adverse events are uncommon and 
self-limited, typically resolving after treatment is discontinued.
Screening for HCV infection is recommended in adults at high risk including those with any 
history of intravenous drug use or blood transfusions prior to 1992.40 Other risk factors 
include chronic hemodialysis, being born to an HCV-infected mother, imprisonment and 
intranasal cocaine and other non-injection drug use.42 The CDC also recommends one-time 
testing without prior ascertainment of HCV risk for adults born between 1945 and 1965, a 
population with a disproportionately high prevalence of HCV infection and related 
disease.43 Anti-HCV antibody testing with subsequent polymerase chain reaction testing for 
viremia is accurate for identifying patients with chronic HCV infection.40
Human Immunodeficiency Virus (HIV)—There is convincing evidence that 
identification and treatment of HIV infection is associated with a markedly reduced risk for 
progression to acquired immunodeficiency syndrome (AIDS), AIDS-related events, as well 
as death in individuals with immunologically advanced disease.28 There is convincing 
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evidence that use of antiretroviral therapy is associated with a substantially decreased risk 
for transmission from HIV-positive persons to their uninfected heterosexual partners. Net 
benefit of screening for HIV infection (anti-HIV antibody test followed by confirmatory 
Western blot or immunofluorescent assay) is substantial.28 However, new testing algorithms 
currently in use do not require performing confirmatory Western blot or immunofluorescent 
assay.44
Evidence is insufficient to determine optimum time intervals for HIV screening; however, a 
reasonable approach is one-time screening to identify those already HIV-positive, with 
repeated screening if at increased risk for HIV infection.28 Screening those aged 15-65 years 
for HIV infection as well as older individuals at increased risk for infection is recommended 
using repeated enzyme immunoassay and if positive, followed by confirmatory Western blot 
or immunofluorescence assay (A recommendation).28 The CDC recommends at least annual 
screening of all individuals at high risk for HIV infection including those initiating treatment 
for tuberculosis or seeking treatment for sexually transmitted diseases, as well as one-time 
screening of all persons 13-64 years of age.45
Syphilis—Although there is no new direct evidence that screening for syphilis infection 
leads to improved health outcomes in persons at increased risk of infection, there is adequate 
evidence that screening tests can accurately detect syphilis infection and that antibiotics can 
cure syphilis.35 Screening and treatment may result in potential harms, including false-
positive results that require clinical evaluation, unnecessary anxiety to the patient, and harms 
of antibiotic use.34,35 Drug-related harms include anaphylaxis from penicillin allergy, and 
Jarisch-Herxheimer reaction occurring within first 24 hours after treatment.36 Screening of 
persons at increased risk for infection is strongly recommended with high certainty that net 
benefit is substantial (A recommendation).
There is no evidence that screening for syphilis infection leads to improved health outcomes 
in persons not at increased risk.35 Therefore, screening is not recommended for nonpregnant 
persons not at increased risk of syphilis infection, and there is moderate to high certainty 
that harms of screening outweigh potential benefits (D recommendation).
Screening for Neoplastic Diseases
Bladder cancer—No randomized trials or high-quality controlled observational studies 
have evaluated clinical outcomes associated with screening compared with not screening for 
bladder cancer.46 Although no study has evaluated the sensitivity or specificity of tests for 
hematuria, urinary cytology or other urinary biomarkers for bladder cancer in persons 
without a history of bladder cancer, positive predictive value of screening tests is less than 
10% even in higher-risk populations.46 No recommendation can be made to screen for 
bladder cancer given that the available evidence is insufficient at this time to objectively 
evaluate the net balance between health benefits and harms of screening (I 
recommendation).
Breast and ovarian cancer susceptibility—The USPSTF recommends that primary 
care providers screen women who have family members with breast or ovarian cancer with 
one of several screening tools designed to identify a family history that may be associated 
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with an increased risk for potentially harmful mutations in cancer susceptibility genes 
(BRCA1 or BRCA2). Women with positive screening results should receive genetic 
counseling and, if indicated after counseling, BRCA testing (B recommendation).47
The Task Force recommends against routine genetic counseling or BRCA testing for women 
whose family history is not associated with an increased risk for potentially harmful 
mutations in the BRCA1 or BRCA2 genes (D recommendation).47
Cervical cancer—Given that benefits of screening substantially outweigh harms, cervical 
cytology every 3 years for women with a cervix who are aged 21-65 years is strongly 
recommended (A recommendation).48 For women aged 30-65 years, a combination of 
cervical cytology and human papilloma virus (HPV) DNA testing every 5 years is also 
strongly recommended instead of cervical cytology screening every 3 years (A 
recommendation).48 Liquid-based cytology has equivalent sensitivity and specificity to 
conventional cytology, and one-time HPV screening is more sensitive than cytology for 
detecting cervical intraepithelial neoplasia (CIN)3+/CIN2+ lesions, but it is less specific.49
Primary HPV screening detects more cases of CIN3+ or cancers in women older than 30 
years, with randomized controlled trials showing mixed results of co-testing in women aged 
30 years or older compared with cytology alone, with no clear advantage over primary HPV 
screening.49 However, more complete evidence is needed before HPV-enhanced primary 
screening is widely adopted for women aged 30 years or older.49
Given the low prevalence of pre-neoplastic lesions in women younger than 21 years of age, 
harms of screening outweigh any potential benefits (D recommendation).48
Also, given low prevalence of pre-neoplastic lesions in women greater than 65 years of age 
with adequate prior negative screenings and not otherwise at high risk of cervical cancer, 
harms of screening in this age group outweigh any potential benefits (D recommendation).48
Harms associated with screening of women with no history of high-grade lesions or cancer 
of the cervix outweigh any potential benefits, particularly after hysterectomy that involves 
removal of the cervix, given the relatively low prevalence of vaginal cancer (D 
recommendation).48
Colorectal cancer—There is convincing evidence that screening with fecal occult blood 
test reduces colorectal cancer mortality in men and women aged 50-75 years (A 
recommendation).50 However, follow-up of positive screening test results requires 
colonoscopy. The primary benefit of the fecal occult blood test compared to flexible 
sigmoidoscopy or colonoscopy is that it may obviate their attendant risks.50 Harms of 
colorectal cancer screening are due to use of invasive procedures in final evaluation of a 
positive test result, and they may arise from preparation of the patient for colonoscopy, 
sedation used during the procedure and the procedure itself, as well as anxiety, 
inconvenience, discomfort, and additional medical expenses. Although evidence about 
harms of fecal occult blood test is lacking, it is expected to be insignificant.
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Fecal occult blood testing is the only diagnostic method with direct evidence for reduction 
of mortality.50 Annual screening is recommended with high-sensitivity tests such as those 
based on fecal immunochemical methods; however, there are no new trials reporting that 
using these methods has an impact on mortality.
Tradeoff between superior sensitivity and reduced specificity occur with high-sensitivity 
guaiac tests.51 There is adequate evidence that benefits of detection and early intervention 
decline after age 75 years.50 Lead time between detection and treatment of colorectal 
neoplasia and mortality benefit is substantial, and competing causes of mortality make it 
progressively less likely that this benefit will be realized in individuals between ages of 76 
and 85 years (C recommendation).
There is adequate evidence that harms of detection and early intervention after age 85 years 
exceed any potential benefits due to other competing causes of mortality at this age group (D 
recommendation).50
There are no trials that report on mortality for fecal DNA testing (I recommendation).50 
Fecal DNA has the potential to be a highly specific test, reducing harms associated with 
follow-up of false-positive test results. These tests are evolving, not widely used, and are 
likely to have a high monetary cost; and information on harms from fecal DNA screening is 
currently limited.50
Lung cancer—Benefits of screening for lung cancer using sputum cytology or any other 
non-laboratory methods have not been established in any group, including asymptomatic 
high-risk populations such as older smokers (I recommendation).52 The balance of benefits 
and harms becomes increasingly unfavorable for persons at lower risk, such as nonsmokers.
Low-dose computed tomography has high sensitivity and acceptable specificity for detecting 
lung cancer in high-risk persons, and it is currently the only recommended screening test for 
lung cancer. Because of high rate of false-positive results, many patients will undergo 
invasive diagnostic procedures as a result of lung cancer screening.52
Although morbidity and mortality rates from these procedures in asymptomatic individuals 
are not available, mortality rates due to complications from surgical interventions in 
symptomatic patients range from 1% to 12%, with morbidity rates ranging from 9% to 44%, 
with higher rates associated with larger resections. Other potential harms of screening are 
anxiety and concern as a result of positive and false-positive results, as well as possible false 
reassurance resulting from false-negative results.52
Ovarian cancer—There is adequate evidence that there is no mortality benefit to routine 
screening for ovarian cancer with single-threshold serum carbohydrate antigen (CA)-125 
testing of asymptomatic women, excluding those with known genetic mutations that 
increase their risk for ovarian cancer.53
Evaluation of abnormal test results consists of either repeated testing or, frequently, removal 
of one or both ovaries by laparoscopy or laparotomy; and there is adequate evidence that 
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screening for ovarian cancer can lead to major surgical interventions in women who do not 
have cancer.53
New evidence about combination of ultrasonography and serological CA-125 test for 
screening suggests that abnormal test results may result in surgery for a substantial 
proportion of women who do not have cancer;54 and there is high certainty that harms of 
screening for ovarian cancer outweigh benefits, leading to the recommendation against 
screening for ovarian cancer in women (D recommendation).55
Pancreatic cancer—There is no evidence that screening for pancreatic cancer is effective 
in reducing mortality.56 There is little new evidence and no critical ongoing studies of 
screening for pancreatic cancer, with the literature noting ongoing research about identifying 
and screening high-risk groups especially with serological markers.57 There is a potential for 
significant harm due to low prevalence of pancreatic cancer, limited accuracy of available 
screening tests, invasive nature of diagnostic maneuvers, and poor outcomes of treatment.56 
As a result, harms of screening for pancreatic cancer exceed any potential benefits, and 
routine screening for pancreatic cancer in asymptomatic adults using serological markers 
such as CA 19-9 is not recommended (D recommendation).
Screening for Substance Abuse
Evidence is insufficient to demonstrate that treatment after use of various illicit drugs 
reliably improves social and legal outcomes for patients, as treatment cannot be directly 
linked to longer term improvements in morbidity or mortality (I recommendation).58 There 
is fair evidence that stopping or reducing drug misuse is related to reduced morbidity and 
mortality, although none of this evidence was derived from individuals screened for drug 
misuse in primary care settings. There is no evidence of harms associated with screening for 
illicit drug use; however, failure to protect the confidentiality of positive results could 
potentially affect a patient's employment, insurance coverage or personal relationships.58
Adverse events ranging from elevated liver function tests to seizures have been reported in 
trials of individuals being treated for illicit drug use with opiate agonists, opiate antagonists 
and antidepressants, with some reported events appearing to be associated with the 
underlying drug use. Toxicological tests of blood or urine can provide objective evidence of 
drug use, but they do not distinguish between occasional users and those who are impaired 
by drug use.58
A Benefit to Public Health
It should be noted that the recommendations of the U.S. Preventive Services Task Force 
(USPSTF) may not be in agreement with some screening recommendations issued by other 
healthcare organizations due to the fact that they are based on the most rigorous assessment 
of scientific evidence, leading to many D and I recommendations. For example, of the 17 
cancer screenings evaluated, only three were A recommendations while 11 were either D 
(eight instances) or I recommendations (see the tables).
Americans tend to be enthusiastic about screening, especially cancer screening.59 What 
could be wrong with screening, especially if it can detect a life-threatening condition at an 
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earlier stage? Are lives being lost to save money? Costs are, however, rarely the reason that 
guidelines set limits on screening; rather, it is the balance of potential harms relative to 
potential benefits. Harms include iatrogenic complications, such as perforation from 
colonoscopy, anxiety over abnormal results, and a cascade of follow-up tests and treatments.
Screening can precipitate over-diagnosis, resulting in the workup and treatment of 
conditions that pose little threat to patients’ health especially when, given a test's 
performance characteristics (clinical sensitivity and clinical specificity), a positive test is not 
adequately predictive of the disease, which is a common situation for many screening tests.
Patients must be adequately informed of the nature and magnitude of the trade-off involved 
with early detection of disease. It is not possible, however, to predict whether greater 
awareness of harms will dampen patients’ enthusiasm for dubious screening tests.59 More 
realistically, resource limitations will intervene: profligate screening practices will become 
increasingly unaffordable in a society struggling with spiraling healthcare costs.
Any society's first concern should be to confirm that health screening provides a net benefit 
to the public's health. This will require that harms be considered independently of costs. 
Until the reality of harms becomes more palpable to clinicians and the public, concerns 
about the safety of screened populations will continue to be mistaken for frugality. 
Furthermore, efforts to control health expenditures should focus not only on the benefits, 
harms and costs of screening tests, but also on their value; i.e., whether they provide health 
benefits that are actually worth their costs or harms to health.60
Early disease detection through screening may offer an opportunity to treat a disease at a 
time when a cure or control of the disease is most likely. However, treatment or over-
treatment of incidental, clinically insignificant disease may result in a more adverse overall 
health outcome compared with no treatment at all. Screening may miss early-stage disease, 
it can detect diseases that are either too advanced or aggressive to respond to treatment, or 
indolent and not likely to produce clinical symptoms. There is likelihood for several adverse 
effects of screening complications from additional diagnostic procedures and unnecessary 
interventions due to false-positive test results; identification and treatment of clinically 
unimportant disease that would not have become clinically apparent in the person's lifetime, 
resulting in increased cost of unnecessary screening; and psychological distress, worry and 
anxiety associated with screening.2
Given the low positive predictive value of many screening tests, a vicious cycle may ensue: 
screening tests may lead to increased risk perception triggered by positive test results that 
are likely to lead to more screening, hence resulting in more false-positive results. In this 
sense, health screening may represent a double-edged sword. On one hand, various diseases 
or conditions may be diagnosed during their asymptomatic phases, providing an opportunity 
for clinical and preventive interventions and increasing the likelihood of more favorable 
health outcomes. On the other hand, over-diagnosis and overtreatment may result, 
particularly when evidence either points to net harm or it is insufficient, conflicting or 
supports only a small magnitude of net benefit.
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False-positive and false-negative results are present using any screening tests. False-positive 
rate becomes more relevant when population prevalence decreases; therefore, some 
screening tests are effective for the high-risk, but not for the general population. False-
positive results are not inconsequential as they may lead to disease labeling and its resulting 
psychological morbidities as well as physical morbidities and mortality that may ensue from 
additional diagnostic tests and explorations.
Lowering the threshold for disease detection may lead to still greater false-positive rates and 
interventions against, and treatment for, inconsequential diseases that in the absence of 
screening may not become clinically apparent and cause any morbidities and mortality 
during a patient's lifetime. Also, a negative screening test result should not be interpreted as 
providing a “clean bill of health.” This is due to false-negative results and limited sensitivity 
of all screening tests.
Potential Outcomes
Outcomes for patients undergoing health screening can be divided into several categories:5
• those with disease which would have been cured by treatment even when 
undetected by screening; in these cases, lives may not be improved by screening 
but earlier detection may impact transmission of some infectious diseases;
• those with incurable disease at the time of screening for whom screening itself may 
not change treatment or outcome but results may impact family, reproductive and 
other decisions as well as transmission of some diseases;
• those dying of co-morbidities other than the screened disease; the quality of life 
may actually be reduced by screening-mediated diagnostic and treatment 
interventions;
• those who are the main beneficiaries of a screening program with diseases which 
may be cured or prevented from being transmitted through screening and early 
detection; and
• those who do not have the disease or condition being screened, usually the largest 
group. Harms to this group are usually minimal unless morbidity and mortality 
resulting from screening is significant.
Screening tests have individual and public health implications. The decision to participate in 
screening can be a matter of individual choice, particularly for diseases or conditions with 
screening recommendation of C or I. This choice may hinge on the probability of various 
outcomes and may depend on the cost of screening and access to it, as well as how 
individuals feel about them.
Screening may save a few lives and reduce morbidity from progressive disease. A few 
people may experience disease-specific morbidities and eventually die of the disease 
anyway. More may face subsequent cascades of diagnostic testing or disease monitoring 
procedures with uncertainties about presence of the disease. Some may be treated 
unnecessarily or experience the morbidities and possibly mortality resulting from the 
treatment. In short, in some cases, whether or not to be screened may be a matter of personal 
Shahangian Page 15
Adv Adm Lab. Author manuscript; available in PMC 2016 February 02.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
choice when magnitude of net benefit is small (C recommendation) or when there is 
insufficient, poor-quality or conflicting evidence supporting a screening test (I 
recommendation).
While these discussions focused on inappropriate overutilization of screening tests, many 
clinical laboratory tests are underutilized as recently documented in a systematic review by 
Zhi, et al.61 These scientists reported that during 1997-2012, there was an overall average 
rate of 45% underutilization of laboratory tests compared to an average rate of 21% for 
overutilization. Pertinent to this report are two conditions, colorectal cancer and chlamydial 
infections, that are under-represented in health screening despite strong (A) 
recommendations. Nationally, annual chlamydia screening rate for females aged 15-25 years 
increased from 25.3% in 2000 to 43.6% in 2006, and then decreased slightly to 41.6% in 
2007, well below 50%.62 Overall, colorectal cancer screening was 58.6% and still well 
below the Healthy People 2020 target of 70.5%.63 The USPSTF has not had the resources to 
evaluate many screening tests, particularly those relating to certain high-risk populations 
that, due to their size, do not represent a significant societal burden of suffering. 
Additionally, the Task Force, in their evaluation of population-based screening tests, has 
focused on primary and secondary prevention as opposed to tertiary prevention and clinical 
intervention. However, other specialty healthcare organizations should consider using the 
evidence-based and rigorous evaluation methods of the USPSTF4 to develop similar 
recommendations for tertiary prevention.
Publication and dissemination of laboratory practice recommendations and guidelines is 
necessary but not sufficient for quality improvement in clinical laboratory practice. Various 
methods should be tried to promote evidence-based and accepted standards of laboratory 
practice and their effectiveness should be evaluated. The approaches that laboratory 
professionals have used to impact optimal utilization of laboratory services have included 
promotion of evidence-based laboratory recommendations and guidelines, provision of 
continuing medical education, periodic clinician feedback, provision of electronic reminders 
and decision-support systems, appropriate changes in laboratory test ordering systems, and 
linking clinical decision support tools to electronic health systems to decrease errors of 
omission.64 Studies should be devised to assess what the motivators and barriers are for 
adoption of good laboratory practices and to how best promote them, including exploration 
of reasons for not following accepted standards of practice so that root causes for non-
adherence could be identified and addressed.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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